Glioblastoma cell ability to adapt their functioning to microenvironment changes is a source of the extensive intra-tumor heterogeneity characteristic of this devastating malignant brain tumor. A systemic view of the metabolic pathways underlying glioblastoma cell functioning states is lacking.
Introduction
Glioblastoma (GBM), the most common form of malignant brain tumors in adults, are characterized by extensive cell heterogeneity which results from irreversible processes -clonal selection of distinct mutations and differentiation of cancer stem cells -but also from the cells' ability to adapt their functioning to variations in their environment and to therapies [2, 13, 32] . As a result, cancer cells coexist within GBM micro-territories in various functioning states, with respect to stem-like, proliferation, metabolic, migration, pro-angiogenic, drug resistance, or tumor-initiating (i.e. tumorigenic) capacities [9, 16, 47, 66] . Such heterogeneity in cell functioning defies therapeutic targeting.
The changes in cell functioning state are accompanied by variations in cell metabolic activities. These variations are essential for GBM cells to exploit different sources of nutrients such as glucose, glutamine or acetate, and thereby cope with changes in oxygen and nutrient availabilities that occur throughout tumor development [45, 46, 49] . The significance of these metabolic variations for the cell behavior may extend beyond a passive response to environmental signals, as recent evidence support a role for metabolism as a driver of changes in cell functional status. Flavahan and colleagues demonstrated that up-regulation of the high-affinity glucose transporter GLUT3 promotes acquisition by GBM cells of tumorigenic properties [23] . Conversely, we found that decreased activity of the mitochondrial enzyme SSADH triggers GBM cell conversion into a less aggressive functioning state, by coupling enhanced levels of the GABA byproduct GHB to altered epigenetic regulations [18] . These metabolic variations have been found to take place within the patient tumors, and to be coherently linked with relevant phenotypic markers [18] , or patients' clinical course [12, 23] . Metabolism is also emerging as a player in GBM therapeutic resistance, as exemplified by escape from the anti-angiogenic Bevacizumab treatment.
This escape has been linked to an increase in glycolysis and its uncoupling from oxidative phosphorylation in favor of lactate production in in vivo GBM models as well as in patients [19] .
Metabolic enzymes are at the core of the molecular pathways controlling cell functioning states.
Correcting their deregulation is therefore expected to be efficient to prevent acquisition and maintenance of aggressive cell functioning states shared by cell subpopulations in all GBM, regardless of their genomic specificities. Exploitation of metabolic targeting for therapies demands therefore to identify the metabolic pathways at play within the patient tumors in link with the heterogeneity of cell functioning states observed in GBM. Here, we used publicly available GBM single cell RNA-sequencing (scRNA-seq) data from four patients with EGFR amplification [14] for identifying metabolic pathways prevailing in GBM cell subpopulations in their most aggressive functioning state (Fig. 1A) .
Transcriptomes obtained by scRNA-seq are endowed with the potential to deliver information on a cell functioning state and its underlying molecular networks. The current analytic methods of scRNA-seq from different tumors result in the predominant grouping of cancer cells according to the tumor from which the cells are isolated (hereafter designed as tumor of origin), whereas normal cells present in the tumor are grouped according to their lineage subtype (e.g. neural, immune, vascular), regardless of their tumor of origin [14, 54, 61] . Characterizing the source of this specific influence of the tumor of origin on cancer cell grouping led to the development of a data reduction approach based on a molecular signature for identifying cell functioning states. Combining analyses of GBM unicellular and tissue transcriptomes with experimental assays, we highlighted a combination of metabolic pathways prevailing in cells with high tumorigenic potential. The analytical method developed is provided.
Material and Methods
All figures were prepared using Adobe Illustrator (Adobe Systems). All bioinformatics analyses were performed using the R software version 3.5.0 (https://cran.r-project.org/). All resources and materials, R packages, corresponding websites and references are listed in Table   S1 . Detailed methods are provided in Supplementary Information 1.
Computational analyses
Single cell transcriptomes of 1033 GBM and 2417 normal cells from four patients were used [14] . This dataset distinguishes cancer from normal cells on the basis of chromosome copy number variation (CNV) profiling, and further distinguishes normal cells according to their neural or immune lineage subtype [14] . Low complexity cell transcriptomes with less than 90000 transcript reads and less than 1700 detected genes were filtered out ( Fig. S1A and B ). We used log2-transformed Counts Per Million (log2(CPM+1)) to allow comparison of read abundance across libraries of different sizes, unless otherwise specified. In an analysis subset, tumor-per-tumor data standardization was achieved by centering and reducing the data on a gene-by-gene basis (Datafile S1). Normalization on the basis of the expression of a set of 17 HKG is detailed in Supplementary Information 1. Tissue transcriptomes corresponded to the TCGA RNA-seq dataset of 155 untreated GBM patients [5] (normalized counts, log2(TPM+0.5), Table S1 ). Grouping analyses were performed using the Hierarchical Clustering on Principal Components (HCPC) approach (Datafile S1). Results were visualized using Principal Component Analysis (PCA) or tdistributed Stochastic Neighbor Embedding (tSNE). HCPC was also used to identify genes whose mean expression in one cluster differs from their mean across all cells (i.e. variables driving cell grouping). Mann-Whitney (Wilcoxon Rank Sum) test with p-values adjusted for multiple testing (Benjamini-Hochberg, p-value < 0.01) was used for differential gene expression analyses between cell or tissue groups [59] . R scripts used for unsupervised grouping and associated analyses are provided in Datafile S1. Normalized Mutual Information (NMI) scores were calculated to determine the contribution of cells issued from distinct tumors to each cluster. A NMI value of 1 implies that clusters gather objects (here, cells) corresponding to a single label (here, the tumor label) whereas a value of 0 denotes that all labels are split across all clusters (Table S1 , [44] ). Tumorigenic scores were obtained by computing the geometric mean of expression values of the signature genes per cell. When null, expression values were imputed a value of 1. Each gene was detected in at least 25% of GBM cells. Gene ontology analysis was done using the human genome as background (Table S1 ). Functional gene network reconstruction was achieved using the information-theoretic method, MIIC (multivariate information-based inductive causation, Supplementary Information 1 [58, 65] ). Four independent datasets comprising 153 to 485 primary GBM transcriptomes were used for patient survival analysis (Table S1 ). Construction of a principal curve was achieved with a PCA based on the expression of each component of the lipid subgroup (16 genes coding for enzymes of the lipid metabolism overexpressed in Tum HIGH cells and tissues and detected in at least 25% of GBM cells, see results). Each cell was projected onto the curve using the Pathifier algorithm (Table S1 , [17] ). Lipid subgroup and vesicle scores (Table S1) were calculated as described for the tumorigenic score.
Biological experiments
Patient-derived cells (PDC) 6240**, R633 and 5706** were obtained from neurosurgical biopsy samples of distinct primary GBM, characterized and cultured as described [18, 57] . (Table S1 ) was achieved as described [4, 18] . Viable cell counting, gene expression analysis, intracranial xenografts, and bioluminescence imaging (Table S1) were performed as described [4, 18] ). All experiments were performed using independent biological samples, each independently repeated at least three times with the exception of the xenograft experiments. Prism 7.0 software (GraphPad) was used for statistical analyses with significance level set at p < 0.05.
Lentiviral transduction

Results
Unsupervised clustering analysis highlights first GBM cells' tumor of origin
We used the publicly available single cell transcriptome dataset from Darmanis and colleagues [14] after removing low-complexity cell transcriptomes. Genes detected in at least 3 transcriptomes were retained for analysis (18577 genes for GBM cells and 19699 genes for normal cells). Previous analyses of GBM and other cerebral tumors scRNA-seq focused on the most dispersed [14] or most expressed genes [22, 50, 62, 64] . These analyses resulted in the identification of cell lineages and cell genomic anomalies rather than cell functioning states. We chose therefore to conserve all potential information by analyzing the full set of selected genes.
Gene expressions were computed as log2(CPM+1). Hierarchical Clustering on Principal Components (HCPC) of gene expressions in the mixed pool of GBM and normal cells readily separated cancer from normal cells ( Fig. S1C ). This result obtained by analyzing all detected genes is similar to the one obtained previously by analyzing the top 500 overdispersed genes [14] .
Separate HCPC of normal cells resulted in six cell groups of immune or neural subtypes (astrocytes, oligodendrocytes, oligodendrocyte precursor cells, neurons, myeloid cells, vascular cells, Fig. 1b 1 ) , each group mixing cells from different tumors ( Fig. 1b 2 ) . In striking contrast, GBM cell clusters resulting from HCPC analysis were dominated by cells from a single patient tumor ( Fig. 1c) . Contribution of the different tumors to clusters was scored by computing Normalized Mutual Information (NMI) between clusters and tumor labels, NMI scores being expected null if each tumor contributes equally to each cluster (Supplementary Material). Fully supporting our observation, the NMI score of normal cell clustering was only of 0.12 whereas the one of tumor cells was of 0.55 (two first bars in Fig. 1d ). This predominant grouping of cancer cells by their tumor of origin has been reported for a number of cerebral and non-cerebral tumors [11, 14, 33, 37, 50, 54, 61] . For identifying traits common to all tumors, data can be analyzed tumor per tumor [62, 63, 69] , or merged and analyzed as a whole after standardization (i.e. subtracting from each expression value the gene expression mean and dividing by its standard deviation across cells within a given tumor) [48] . The numbers of cancer cells precluding confident per-tumor analysis, we turned to standardization. HCPC analysis of standardized data resulted in clusters mixing cells from different GBM ( Fig. 1e) , as shown by a NMI score similar to the one calculated for normal cell grouping (third bar in Fig. 1d ). However, gene ontology analysis of the genes identified in the HCPC as driving the cell grouping (see methods) did not provide clear links between cell clusters and potential cell functioning states ( Fig. 1f , Table S2 ).
These results prompted us to further explore non-standardized data for minimizing the factors that might account for predominant grouping of cancer cells according to their tumor of origin.
Tumor identity encoded by information dispersed through GBM cell transcript repertoires
Two main factors can account for tumor-driven cell grouping: the technical variations in tumor sample scRNA-seq, collectively referred to as batch effect, and the biological tumor-specific variations.
In scRNA-seq experiments, batch variations in RNA quality and sequencing efficiency, regardless of their origin, translate into variations in sample-dependent gene detection failures (referred to as dropouts) and in sample sequencing depth. Grouping of normal cells independently from their tumor of origin indicates that such batch variations are minor. We tested the influence of dropouts and of an additional normalization of the sequencing depth using a set of GBM-specific housekeeping genes (HKG) on the cell grouping (Table S3 ). Neither dropout imputation nor HGK normalization corrected tumor-driven cell grouping ( Fig. 1d, Fig. S2A and B), confirming that batch effects are not major contributors of this grouping. Inter-tumor biological differences encompass genomic alterations known to vary greatly from one GBM to another, the tumor developmental stage, or the brain area and/or cells from which it developed [55] . We reasoned that differing biological characteristics, whatever their source, would translate into gene repertoires differing between tumors. To test this possibility, we considered binarization of the data by applying a value of one to all expressed genes regardless of their relative expression levels, and zero for nondetected ones. Maintenance of cell grouping by tumor of origin following binarization of gene expression ( Fig. 1d and Fig. S2C ) showed that cell gene repertoires are more similar within a given tumor than between two different tumors. We therefore sought to better understand which genes contribute most to this variability between cell transcriptomic landscapes. We first tested the impact of chromosome CNV on the cell grouping by filtering out genes mapped to chromosomes with CNV as previously identified [14] . Taking into account CNV did not modify tumor-driven cell grouping ( Fig. 1d and Fig. S2D ). Likewise, excluding genes detected in a single tumor or including only genes detected in all tumors did not change the outcome of HCPC analyses ( Fig. 1d and Fig. S2E and F). We then tested the influence of inter-tumor variability in gene expression. Exclusion of the 100 genes identified as differentially expressed between tumors by Darmanis and colleagues [14] did not modify the outcome of the analysis ( Fig. 1d and Fig. S2G ). We then considered the most expressed genes, calculating the aggregate expression of each gene across cells, and retaining genes with the highest aggregate expression as described [62] . HCPC using the resulting 9505 most expressed genes still grouped cells by their tumor of origin ( Fig. 1d and Fig. S2H ). Likewise, performing HCPC using the top 500 or 1000 genes with expression variability between cells higher than expected (i.e. overdispersed [20] ), or after excluding them, resulted in a similar tumor-driven cell grouping ( Fig. 1d and Fig. S2I -L). Altogether, these results indicate that tumor-driven cell grouping is not based on limited and tumor-specific sets of genes. This led us to envisage that primary grouping of cancer cells by tumor of origin could result from information dispersed throughout the whole cell transcriptome. We challenged this hypothesis by performing iterative HCPC analyses on decreasing numbers of genes randomly selected among the 18577 detected genes. Ten analyses of distinct sets of randomly selected genes were performed for each size of gene sets (n = 2000, 1000, 500, 250, 100, and 50). NMI scores of the clusterings remained unchanged for gene set sizes > 500 ( Fig. 2a and b ). Their gradual decrease below this threshold indicated a progressive reduction of the influence of the tumor of origin on cell grouping. This influence was suppressed only when reducing the number of analyzed genes to 50, as shown by NMI scores equivalent to that calculated from the grouping analysis of the 19699 genes detected in normal cells ( Fig. 2a and c). Altogether, these results show that tumor-driven cell grouping is irreducible to differential expression of circumscribed gene groups. To the contrary, it is encoded by information dispersed throughout the cell transcript repertoires, which is retrieved as soon as a combination of expressions of more than 500 genes is included in the analyses. As a consequence, unsupervised analysis turns out to be inadequate for identifying cell functioning states common to all tumors. We thus turned towards an approach of data reduction based on a signature of a functionally coherent set of genes.
GBM cell grouping according to their tumorigenic potential upon signature-driven reduction of scRNA-seq data
We developed a grouping method based on a molecular signature we previously identified [4] . The signature is composed of five transcription factors, ARNT2, POU3F2, OLIG2, SOX9 and SALL2, with co-varied expression in GBM tissues and cells [4] . The POU3F2, OLIG2 and SOX9 genes have regulatory elements with ARNT2 binding sites and are down-regulated upon ARNT2 knockdown [4] . Each signature element was demonstrated to be required for GBM cell tumorigenic properties [4, 28, 41, 60] . We sought to use this signature to highlight subpopulations of cells in a tumorigenic state, expected to be present in all tumors.
To obtain an index of the cells' tumorigenicity, we calculated a tumorigenic score corresponding to the geometric mean of the expression of each signature element. The score distribution curve exhibited a main inflection point corresponding to the distribution's mean ( Fig.   3a ), which delineated two groups of 654 and 379 cells with low and high tumorigenic scores, respectively, hereafter designed as Tum LOW and Tum HIGH (Fig. 3a) . Each of the four tumors contributed to each group (Fig. 3b , NMI score=0.057). Tum HIGH GBM cells exhibited higher numbers of transcripts and genes than Tum LOW GBM cells ( Fig. S3A and B) . We identified 6630 genes differentially expressed between both groups (Mann Whitney, BH-adjusted p-value < 0.01, Table S4 ), 98% of these genes being overexpressed in Tum HIGH GBM cells. Of note, several items of the list of genes with enhanced expression in Tum HIGH cells encoded proteins previously implicated in GBM cell aggressiveness (e.g. E2F1 [67] , EGFR [1] , HES1 and NOTCH1 [7] , FABP7 [15] , PTPRZ1 [24] ). Conversely, genes with known tumor-suppressor properties were identified among the genes overexpressed in Tum LOW cells (e.g. TUSC3 [34] , SERPINB1 [31] ). The whole workflow is summarized in Fig. S4 and provided in Datafile S2. These results suggest that cell functioning state can be inferred from scRNA-seq data following signature-driven data reduction.
We next challenged the relevance of this approach by applying it to an independent dataset and using in vitro and in vivo GBM models.
Specific amino acid and lipid metabolic pathways distinguish GBM cells and tissues with high tumorigenic potential
To probe the biological relevance of our approach, we first applied the same analytical strategy to an independent dataset. Additional GBM single cell transcriptome datasets equivalent to the one published by Darmanis and colleagues and including several patients are not publicly available. We therefore turned to the TCGA collection of transcriptomes obtained by sequencing the RNA extracted from 155 patients' GBM tissue fragments. As expected with respect to the heterogeneous nature of GBM tumors where cancer cells with differing properties co-exist with normal neural, vascular and immune cells, we observed a smoother distribution curve of the tumorigenic score across GBM tissues than across GBM cells ( Fig. 3c ). We therefore used quartiles to delineate two GBM tissue groups with low and high tumorigenic scores, respectively ( Fig. 3c ). Differential expression analysis between these two groups yielded a list of 6565 genes, 44% of them being overexpressed in Tum HIGH GBM tissues (Mann Whitney, BH-adjusted p-value < 0.01, Table S4 ). The list of genes overexpressed in Tum HIGH GBM tissues showed a 65.5% overlap with the list of genes overexpressed in Tum HIGH cells ( Fig. 3d , Table S4 ). This result was remarkable considering that it was obtained by confronting a dataset derived from 4 tumors to another derived from 155 tumors, and that tissue transcriptomes correspond to gene expression levels averaged over several hundred thousands of cells. Of the 1688 genes overexpressed in Tum HIGH GBM cells and tissues, 78 encoded metabolic enzymes (Table S5 ). We further selected the 66 of them significantly correlated to the tumorigenic score across all GBM cells as well as across all GBM tissues (Pearson correlation, p-value <0.01, Table S5 ). Gene ontology analysis highlighted a 15 to 45-fold enrichment first in components of the lipid metabolism (27 genes) and second in components of the amino acids metabolic pathways (18 genes) ( Fig. 4a , Table S5 and Functional association of the lipid metabolism enzyme ELOVL2 to patient clinical outcome and GBM development ELOVL2 is a fatty acid elongase involved in the elongation of 22-to 24-carbon VLC-PUFA [27] . In agreement with ELOVL2 overexpression in Tum HIGH cells, we observed ELOVL2 overexpression in cells with tumorigenic properties in an independent transcriptome dataset of human GBM cells in culture [38] (Fig. Fig. S6A ). In addition, we observed a higher expression of ELOVL2 in GBM than in normal brain tissues ( Fig. S6B ), as well as in single GBM cells compared to single normal cells ( Fig. S6C ). Its expression was also higher in primary GBM characterized by a wild-type form of IDH1 compared to diffuse glioma, which are characterized by a mutant form of IDH1 ( Fig. S6D ). Of note, ELOVL2 levels were also higher in GBM bearing an amplified EGFR gene than in GBM with non-amplified EGFR (Fig. S6E ). Finally, ELOVL2 high expression was found to be associated with worse patient survival in independent patient cohorts ( Fig. 5a Tumor development monitoring with bioluminescent imaging showed delayed tumor formation and reduced tumor burden in mice grafted with shELOVL2-PDC, compared to mice grafted with shControl-PDC ( Fig. 5d and e ). Of note, tumors that developed in a delayed manner from xenografts of shELOVL2-PDC had escaped from ELOVL2 inhibition, as shown by Q-PCR detection of human ELOVL2 mRNA levels at levels similar to those measured in tumors developing from xenografts of shControl-PDC ( Fig. 5f ). To gain insight into the cell process affected by ELOVL2, we selected from the 27 genes of the lipid metabolism, a lipid subgroup of 16 genes detected in at least 25% of the cells (Table S5 ). These genes were used to construct a principal curve onto which each GBM cell was projected (Fig. 5g ). In addition, we computed a score with the expression of these 16 genes, following the same procedure as for the tumorigenic score. Of note, highest lipid scores (Fig. 5h ), highest ELOVL2 expression values ( Fig. 5i ) and highest tumorigenic scores ( Fig. 5j ) all coincided in cells along the principal curve. This result further strengthens the relationship between the expression of the lipid subgroup, ELOVL2 expression and the tumorigenic state of the cells. Another member of the ELOVL family, ELOVL4, was involved in extracellular vesicle formation and release [29] . This prompted us to determine whether ELOVL2 expression is associated with molecular signatures of extracellular vesicles at the single cell level. Scores calculated for each of the four molecular signatures associated with extracellular vesicle were correlated with the tumorigenic scores (Table S6 ) and coincided with high ELOVL2 expression in cells along the principal curve ( Fig. 5k and Fig. S7 ). This experimental set of results demonstrates that ELOVL2 is required for the tumorigenic behavior of GBM cells. It also suggests that ELOVL2 requirement stems from its involvement in the regulation of intercellular communication via extracellular vesicles. In addition, it provides robust experimental support for the relevance of signature-driven reduction of single cell transcriptomes to decipher the metabolic pathways underscoring GBM cell behaviors within the patients' tumors.
Discussion
Metabolism is at the heart of cell behavior and its dependence on enzymatic activities makes it a target of choice for therapeutic targeting. GBM cells adapt their functioning state to changes in their microenvironment, whether these changes result from natural tumor growth or therapies.
Progress towards identification of the most relevant possible targets for patient therapy requires access to molecular players active in the actual context of the patient tumors while taking into account the heterogeneity of the tumor tissue. Transcriptomes of single cells sorted from patient GBM offer such an access.
Unsupervised analysis of scRNA-seq resulting in predominant grouping of cancer cells according to their tumor of origin and of normal cells independently from their tumor of origin was found in analyzing scRNA-seq from tumors other than GBM [11, 33, 37, 54, 61] but never questioned. We considered in all ways we thought eventual influences of scRNA-seq technical biases as well as of the tumor-specific differences in gene repertoires expected to reflect intertumor biological differences whatever their sources. We did not find one accounting for cell grouping-dependence on the tumor of origin. In contrast, unsupervised analyses of randomly down-sampled numbers of genes showed that tumor-driven cell grouping disappears below a critical number of genes (100 to 50 in this study). Collectively, our results show that cancer cell clustering per tumor is not due to scRNA-seq technical bias (as expected with respect to the lack of influence of the tumor on normal cell grouping) or to circumscribed gene subsets reflecting intertumor biological differences. They support the notion that the identity of the tumor to which each cancer cell belongs is encoded by information dispersed throughout the cell transcript repertoire.
To unmask cell functioning states regardless of their tumor of origin, we reduced the data based on previously acquired biological knowledge. Signature-driven data reduction was previously used to infer cell lineages from single cell transcriptomes of oligodendrogliomas and diffuse infiltrative pontine gliomas [22, 62] . In these studies performed on centered data, cell lineages were inferred using sets of top correlated genes to the principal component scores of a PCA of the dataset under scrutiny [62] , or on the basis of mouse or human gene sets differentiating normal neural subtypes [22, 64] . Here, we based our analysis on a molecular signature related to a major functioning state, tumorigenicity.
Cells from a given GBM have long been known to be endowed with differing abilities to initiate neoplasms [30, 53, 66] . We postulated that such a choice would enhance the likelihood to group cells based on their functioning state irrespective of their tumor of origin. We postulated also that using a signature defined [4] and experimentally validated in independent prior studies [4, 28, 41, 60] would reduce the risk of obtaining results relevant only for the dataset analyzed. Our choices proved fruitful to identify two contrasting functioning states, with respect to the following findings: genes previously described as controlling GBM cell aggressiveness were found to be overexpressed in cells with high tumorigenic scores; a highly similar list of differentially expressed genes was obtained when applying the same analytical strategy to an independent dataset made of tissue bulk transcriptomes of a much larger number of GBM; highest scores for the lipid subgroup found to be enriched in Tum HIGH cells and tissues coincided with highest tumorigenic scores; finally, experimental knockdown of the most interconnected gene of this lipid metabolism subset, ELOVL2, impaired GBM cell tumorigenic properties.
Oncogenic mutations have long been known to favor mobilization of metabolic pathways, most notably by allowing cancer cells to adapt their mode of energy production to different microenvironments and sources of nutrients [40, 52] . GBM cells, like other cancer cell types, are considered to favor glycolysis over oxidative phosphorylation for ATP production. This prevalence of glycolysis is considered as a cell adaptation to its need for feeding carbon into biosynthesis of nucleic acids, fatty acids and proteins for cell growth and proliferation. At the single cell level, overexpression of genes coding for enzymes of the glycolysis pathway was not associated with high tumorigenic scores. This suggests that enhanced mobilization of glycolysis enzymes is not proper to GBM cells in a tumorigenic state, at least at the transcriptional level. Overexpression of two genes coding for enzymes of the amino-acid pathways, GATM and CKB (Fig. 4b ) rather
suggests that another source of energy distinguishes tumorigenic from non-tumorigenic GBM cells.
GATM is one of the two enzymes ensuring brain-endogenous synthesis of creatine, starting from glycine. The second enzyme, GAMT, was found to be overexpressed in tumorigenic high GBM cells but not retained for final analyses because absent from the list of genes overexpressed in tumorigenic GBM tissues. CKB is responsible for the phosphorylation of creatine, which serves for ATP regeneration and plays an essential role in brain energy metabolism [56] . Interestingly, GATM is the most interconnected of the enzymes coding for elements of amino acid metabolism in the modeling of the gene expression network (Fig. 4c ). Lipids are also a significant source of energy.
Lipid metabolism association to GBM cell aggressiveness has been reported to stem from lipid contribution to cell energetics through fatty acid beta-oxidation and to transduction pathways through the mevalonate metabolism [40] . Accordingly, we found that genes coding for key enzymes of the fatty acid synthesis (e.g. ACLY, FASN) and beta-oxidation pathways (CPT1), as well as the mevalonate pathways (MVD) were overexpressed in Tum HIGH cells. In addition, we observed an overexpression of genes involved in the synthesis of phospholipids, glycerolipids and sphingolipids, essential components of plasma membranes and/or sources of potent autocrine/paracrine signaling molecules.
The biological relevance of the results of our bioinformatics analyses was further validated in in vivo experimental models of human GBM. Our study unveiled an unexpected causal link between ELOVL2, the endpoint enzymatic component of the lipid subpathway ensuring synthesis of VLC-PUFA, and the tumorigenic status of GBM cells. Notably, we show that ELOVL2 knockdown in PDC decreases tumor growth in vivo. Little is known on this member of the ELOVL family that catalyzes the elongation of saturated and monounsaturated VLCFA (ELOVL1, 3, 6 and 7) and of VLC-PUFA (ELOVL2, 4 and 5) by adding two carbon units to the carboxyl end of a fatty acid chain [27] . ELOVL2 is specifically involved in the elongation cascade starting from the dietary PUFA linoleic and linolenic acids, which cannot be synthesized by humans. The products of the enzymatic process of these essential PUFA are thought to modulate diverse biological phenomena ranging from cell survival to inflammatory responses [3, 10] . In mouse models, Elovl2 knockout has been shown to result in defective PUFA composition in the liver, serum and testis in association with male infertility and a reduced capacity to accumulate fat [51, 70] . PUFA are structural components of membrane phospholipids especially enriched in neural tissues, and provide potent signaling compounds [39] . In the MCF7 cell line that models breast cancers requiring estrogen for growth, ELOVL2 expression is positively regulated by estrogen [26] , and its knockdown is associated with epithelial to mesenchymal transition [36] . In this epithelial cancer high ELOVL2 expression is associated with higher metastatic relapse-free survival [36] . On the opposite, ELOVL2 upregulation in prostate cancer has been associated with the oncogenic effect of SPOP loss of function mutations [68] . Here, finding of the association between high ELOVL2 expression in GBM and worsened patient prognosis ( Fig. 5a and Fig. S6F) , coupled with the demonstrated requirement of ELOVL2 for GBM cells tumorigenicity in vivo, demonstrates a causal link between ELOVL2 and GBM growth. We investigated through bioinformatics analysis what might be the mechanism of action of ELOVL2 overexpression in tumorigenic high cells. The correlation between ELOVL2 overexpression and molecular signatures of extracellular vesicles suggests that formation and release of extracellular vesicles is one of the cell processes by which ELOVL2 controls GBM tumor development. This possibility is coherent with the reported involvement of another member of the family, ELOVL4, in the formation of synaptic vesicles in the brain and retina [29] .
Extracellular vesicles have been involved in intercellular communications within GBM, by carrying metabolites, nucleotides and proteins able to affect the behavior of cancerous as well as noncancerous cells composing the tumor [6, 21] . Our experimental results are coherent with our modeling results that place ELOVL2 at the core of the metabolic pathways essential for sustaining GBM cell tumorigenicity. ELOVL2 importance for GBM is strengthened by a study published during writing of this article that describes ELOVL2 as a super-enhancer associated gene controlling glioblastoma stem cell properties [25] .
Conclusions
The present findings underscore the power of single cell transcriptome analyses for unveiling the complexity of the participation of metabolism in relation to the heterogeneity of cell functioning states encountered in GBM. It is worth emphasizing that the discovery of a molecular deregulation that proved to be a predictor of patient survival in independent cohorts of several hundred tumors stems from the study of cells derived from only four tumors. Our results show the high relevance of integrating the cell functioning status, even when focusing on only two contrasting states, for the discovery of metabolic modules controlling GBM aggressiveness. Further development of signature-driven data reduction based on established experimental evidence will lead to further refine the identification of functioning states and of the diversity of the molecular networks required for their maintenance. The workflow we designed to classify any single cell dataset according to a signature score will be instrumental for blocking GBM cell ability to escape therapies, thus contributing to improve GBM therapies. 
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Datafile S1. R scripts used for unsupervised grouping and associated analyses. Computing gene expression values with the log2(CPM + 1) allows correcting sequencing depth variations between samples. We tested an additional step in the normalization of the sequencing depth based on a set of housekeeping genes (HKG). We considered as HKG the cluster of genes detected in at least 90% of the cells with pairwise correlated expression and the lowest coefficient of variation across cells. The geometric means of HKG expression were calculated per small groups of cells with similar expression profiles (metacells). Gene expression values computed as log2(CPM + 1) were divided, for each cell, by the normalization factor corresponding to its metacell. The analytical method developed has been implemented in R and is provided in Datafile S2. Mann-Whitney test. TCGA tissue transcriptome dataset (microarrays) of 528 primary GBM and 10 normal brain tissues. C. Significantly higher ELOVL2 expression in GBM cells compared to normal cells. Mann-Whitney test. scRNA-seq dataset from Darmanis and colleagues [14] . D-E. ELOVL2 expression prevails in GBM bearing a wild-type form of IDH1 (D) and with EGFR gene amplification (EGFR AMP ) (E). French tissue transcriptome dataset (microarrays 
